Physician profile
Haley Koepp
NPI 1134618341
$4,568.28
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,259 · 2022: $2,080 · 2023: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $229.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $833.00 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $575.52 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $523.19 | 2021-2023 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $508.49 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $487.13 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $272.06 | 2021-2022 | |
| Orexo US, INC. | $239.07 | 2021 | |
| Vanda Pharmaceuticals INC. | $234.84 | 2021-2022 | |
| Lundbeck LLC | $161.58 | 2021-2022 | |
| Alkermes, INC. | $153.38 | 2021-2023 | Aristada, Lybalvi |
| Indivior INC. | $88.46 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.75 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $76.48 | 2021-2022 | |
| Axsome Therapeutics, INC. | $65.59 | 2022-2023 | Auvelity |
| Arbor Pharmaceuticals, INC. | $62.34 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $57.26 | 2022 | |
| Merck Sharp & Dohme LLC | $43.76 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $29.54 | 2022 | |
| Eisai INC. | $27.21 | 2021 | |
| Bausch Health US, LLC | $14.06 | 2022 | |
| Avanir Pharmaceuticals, INC. | $13.09 | 2021 | |
| Neos Therapeutics, Lp | $13.03 | 2021 | |
| Adlon Therapeutics L.P. | $12.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Koepp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.